🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesGLP-1 and arterial inflammation — what worked for you? Page 3

GLP-1 and arterial inflammation — what worked for you?

PeptideSynthNJ Mon, May 26, 2025 at 3:55 AM 14 replies 1,510 viewsPage 3 of 3
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
May 28, 2025 at 5:47 AM#11
sarah_TO said:
LipidDoc_ATL said: ...we don't know the long-term effects of cardiovascular risk...

I'm 48 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

10 months later: down 57 lbs, off metoprolol, A1C from 7.4% to 5.2%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

Last edited: May 28, 2025 at 11:47 AM
18 18kim_atl_prep, sarah_TO, wendy_avl and 15 others
Reply Quote Save Share Report
DeniseRN_TPA
Member
345
1,567
Aug 2024
Tampa, FL
May 28, 2025 at 5:38 PM#12
stefan_berlin said:
SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk.

This is exactly what I could not find anywhere else.

17 17hyun_seoul, jim_asheville, matt_MKE and 14 others
Reply Quote Save Share Report
carl_compliance
Member
234
1,123
Nov 2024
Raleigh, NC
May 29, 2025 at 5:29 AM#13
sarah_TO said:
LipidDoc_ATL said: ...we don't know the long-term effects of cardiovascular risk...

CRP reduction on cardiovascular risk — this is the lab result that excites me most:

Baseline hsCRP: 10.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 2.5 mg/L (moderate risk)
Month 12 hsCRP: 0.4 mg/L (low risk)

This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 17% to 5%. My cardiologist is genuinely impressed.

Last edited: May 29, 2025 at 8:29 AM
16 16ricardo_MIA, BrianDallas92, labquiet_amy and 13 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.PathRoch
Member
456
2,123
Jun 2024
Rochester, MN
May 29, 2025 at 5:20 PM#14
PeptideSynthNJ said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

15 15SaraMom3, Dr.MetabolicMD, RetaRick_CA and 12 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
May 30, 2025 at 5:11 AM#15

Moderator note: the sourcing question belongs in the vendor section and has been split out.

14 14PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 11 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register